Bio

Dr Mark Linch is a Medical Oncologist specialising in the management of patients with prostate cancer and bladder cancer. He has a particular interest in tailoring immunotherapy, hormonal treatment and chemotherapy based on the molecular and clinical features of individual patients. For example:

• Checkpoint inhibitors
• Antibody drug conjugates
• Chemotherapy
• Tumour profiling
• Liquid biopsies

Dr Linch is an Associate Professor at University College London (UCL) Cancer Institute, where he leads the Urological Cancer Biology Group, and Honorary Consultant Medical Oncologist. Dr Linch trained in medical oncology at the Royal Marsden Hospital (RMH), London. In 2012 he was awarded a PhD in Cancer Cell Biology from UCL and the Cancer Research UK London Research Institute (LRI), now known as the Francis Crick Institute. He continued his post-doctoral studies at the LRI while also working as a Consultant Medical Oncologist at RMH. In 2014 Dr Linch moved to UCL to specialise in the clinical management and translational biology of prostate and bladder cancer.

His research is focused on the immune biology of these cancers with a view to identifying rational immunotherapy combinations, predictive biomarkers and novel liquid biopsy strategies. He is chief investigator of a number of national and international combination immunotherapy trials in bladder and prostate cancer, is Chair of the UK Prostate Cancer 100,000 genome project group and is an inaugural member of the UK Bladder Cancer Translational Group.